Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users.

Open forum infectious diseases

Buehrle DJ, Shields RK, Shah N, Shoff C, Sheridan K.
PMID: 28680904
Open Forum Infect Dis. 2017 May 23;4(3):ofx102. doi: 10.1093/ofid/ofx102. eCollection 2017.

Sixty-one percent of intravenous drug users (IVDUs) who received outpatient parenteral antibiotic therapy (OPAT) failed treatment. Hospital readmission and adverse drug reactions occurred in 25%. By multivariate analysis, time since last IVDU was associated with failure (

Cite
Buehrle DJ, Shields RK, Shah N, et al. Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users. Open Forum Infect Dis. 2017;4(3):ofx102doi: 10.1093/ofid/ofx102.
Buehrle, D. J., Shields, R. K., Shah, N., Shoff, C., & Sheridan, K. (2017). Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users. Open forum infectious diseases, 4(3), ofx102. https://doi.org/10.1093/ofid/ofx102
Buehrle, Deanna J, et al. "Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users." Open forum infectious diseases vol. 4,3 (2017): ofx102. doi: https://doi.org/10.1093/ofid/ofx102
Buehrle DJ, Shields RK, Shah N, Shoff C, Sheridan K. Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users. Open Forum Infect Dis. 2017 May 23;4(3):ofx102. doi: 10.1093/ofid/ofx102. eCollection 2017. PMID: 28680904; PMCID: PMC5493937.
Copy Download .nbib Format: NLM
Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant .

Open forum infectious diseases

McCreary EK, Byers KE, Fernandes C, Kline EG, Nicolau DP, Shields RK.
PMID: 33409327
Open Forum Infect Dis. 2020 Nov 12;7(12):ofaa549. doi: 10.1093/ofid/ofaa549. eCollection 2020 Dec.

We report a case of multidrug-resistant

Cite
McCreary EK, Byers KE, Fernandes C, et al. Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant . Open Forum Infect Dis. 2020;7(12):ofaa549doi: 10.1093/ofid/ofaa549.
McCreary, E. K., Byers, K. E., Fernandes, C., Kline, E. G., Nicolau, D. P., & Shields, R. K. (2020). Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant . Open forum infectious diseases, 7(12), ofaa549. https://doi.org/10.1093/ofid/ofaa549
McCreary, Erin K, et al. "Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant ." Open forum infectious diseases vol. 7,12 (2020): ofaa549. doi: https://doi.org/10.1093/ofid/ofaa549
McCreary EK, Byers KE, Fernandes C, Kline EG, Nicolau DP, Shields RK. Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant . Open Forum Infect Dis. 2020 Nov 12;7(12):ofaa549. doi: 10.1093/ofid/ofaa549. eCollection 2020 Dec. PMID: 33409327; PMCID: PMC7751399.
Copy Download .nbib Format: NLM
Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in .

Open forum infectious diseases

Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ.
PMID: 28685153
Open Forum Infect Dis. 2017 Jul 01;4(3):ofx101. doi: 10.1093/ofid/ofx101. eCollection 2017.

We used meropenem to successfully treat a patient with bacteremia due to ceftazidime-avibactam-resistant, meropenem- susceptible

Cite
Shields RK, Nguyen MH, Press EG, et al. Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in . Open Forum Infect Dis. 2017;4(3):ofx101doi: 10.1093/ofid/ofx101.
Shields, R. K., Nguyen, M. H., Press, E. G., Chen, L., Kreiswirth, B. N., & Clancy, C. J. (2017). Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in . Open forum infectious diseases, 4(3), ofx101. https://doi.org/10.1093/ofid/ofx101
Shields, Ryan K, et al. "Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in ." Open forum infectious diseases vol. 4,3 (2017): ofx101. doi: https://doi.org/10.1093/ofid/ofx101
Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in . Open Forum Infect Dis. 2017 Jul 01;4(3):ofx101. doi: 10.1093/ofid/ofx101. eCollection 2017. PMID: 28685153; PMCID: PMC5493938.
Copy Download .nbib Format: NLM
Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.

Antimicrobial agents and chemotherapy

Biagi M, Butler D, Tan X, Qasmieh S, Tejani K, Patel S, Rivosecchi RM, Nguyen MH, Clancy CJ, Shields RK, Wenzler E.
PMID: 31527035
Antimicrob Agents Chemother. 2019 Sep 16; doi: 10.1128/AAC.01085-19. Epub 2019 Sep 16.

The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated. In vivo, mean (± SD) plasma PK parameters of isavuconazole were:

Cite
Biagi M, Butler D, Tan X, et al. Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2019;doi: 10.1128/AAC.01085-19.
Biagi, M., Butler, D., Tan, X., Qasmieh, S., Tejani, K., Patel, S., Rivosecchi, R. M., Nguyen, M. H., Clancy, C. J., Shields, R. K., & Wenzler, E. (2019). Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy. Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.01085-19
Biagi, M, et al. "Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy." Antimicrobial agents and chemotherapy vol. (2019). doi: https://doi.org/10.1128/AAC.01085-19
Biagi M, Butler D, Tan X, Qasmieh S, Tejani K, Patel S, Rivosecchi RM, Nguyen MH, Clancy CJ, Shields RK, Wenzler E. Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2019 Sep 16; doi: 10.1128/AAC.01085-19. Epub 2019 Sep 16. PMID: 31527035; PMCID: PMC6879253.
Copy Download .nbib Format: NLM
Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies.

Journal of fungi (Basel, Switzerland)

Clancy CJ, Shields RK, Nguyen MH.
PMID: 29376927
J Fungi (Basel). 2016 Feb 06;2(1). doi: 10.3390/jof2010010.

Mortality rates due to invasive candidiasis remain unacceptably high, in part because the poor sensitivity and slow turn-around time of cultures delay the initiation of antifungal treatment. β-d-glucan (Fungitell) and polymerase chain reaction (PCR)-based (T2Candida) assays are FDA-approved adjuncts...

Cite
Clancy CJ, Shields RK, Nguyen MH. Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. J Fungi (Basel). 2016;2(1)doi: 10.3390/jof2010010.
Clancy, C. J., Shields, R. K., & Nguyen, M. H. (2016). Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. Journal of fungi (Basel, Switzerland), 2(1), . https://doi.org/10.3390/jof2010010
Clancy, Cornelius J, et al. "Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies." Journal of fungi (Basel, Switzerland) vol. 2,1 (2016). doi: https://doi.org/10.3390/jof2010010
Clancy CJ, Shields RK, Nguyen MH. Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. J Fungi (Basel). 2016 Feb 06;2(1). doi: 10.3390/jof2010010. PMID: 29376927; PMCID: PMC5753091.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries